Rigel Pharmaceuticals, Inc. is a pharmaceutical company based in the USA with a medium risk ESG score of 26.6. Specializing in developing small-molecule drugs for autoimmune, cancer-related, and viral diseases, the company's lead drug, licensed to AstraZeneca, focuses on oral rheumatoid arthritis treatment. Rigel's pipeline products include TAVALISSE tablets as well as a range of innovative drug candidates.